Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company.
Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers - Cancers - Ovarian, Peritoneal
Products, services, technology
Cooperation possibilities
Following a first licensing agreement for AUP-16 in China, we have an IND approval for a Clinical study on Diabetic Foot Ulcers to be conducted in China.
We are now aiming for a global licensing agreement - or multiple regional licensing - for AUP-16.
Some insights
We are a Cell and Gene Therapy Platform Company with exciting Phase-2 data at hand. Our multi-targeting products, based on genetically modified safe lactic acid bacteria, address broad unmet medical needs: Chronic Wounds - diabetic foot ulcers, venous ulcer - Ovarian Cancer, Inflammatory diseases.
With multitargeting products addressing complex multi-factorial diseases, we create a better future for patients suffering from chronic wounds, cancers, inflammatory diseases
Our team has demonstrated business acumen, scientific expertise, fundraising experience
We have raised 48MCHF to date. We have opened a 35MCHF series B round and will wecome new investors
Venture Capital Firms, Private Equity, Family Offices & HNWI
